You are offline. Saved alerts are still available. Live updates resume when you reconnect.
Reading a stock page
- The tabs show the price chart, results, shareholding, events and news for this one company.
- The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
- Every figure names its source. "Official" means it came from NSE or BSE filings.
- Use the star to watch the stock, or Add to portfolio to record a trade.
🎯 Buy It or Not? — Complete Intraday to Long-Term Decision Report for AARTIPHARM (NSE)
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
80
ISA Signal Score: Strong setup
Trend100
Momentum83
52-week range100
Volume85
Risk56
Fundamentals60
Working for it
- Price is above its 20-day average
- Price is above its 50-day average
- Price is above its 200-day average (long-term uptrend)
- 50-day average is above the 200-day average
- 50-day average is rising
- RSI 67: healthy strength
Working against it
- Revenue fell 5% year on year
At a glance
QualityAverageROE 13.1%, ROCE 18.0%, debt 0.15x equity
GrowthNot knownNeeds at least 3 years of results. More years load on later visits.
ValuationFairP/E 42.8 vs sector median 42.8, 5.3x book
MomentumStrongAbove its 200-day average, beat NIFTY 50 by 46.7 points
RiskHighSwings 47% a year, fell up to 26% from a peak, beta 1.17
Smart Investor Tips: AARTIPHARM
Constructive Setup (Trend + Fundamentals Aligned)Actionable Insights & Positives
- Confirmed uptrend: trading above both rising 50-day (Rs 899.91) and 200-day (Rs 760.39) averages.
- Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.
Risk Checks & Things to Verify
- High 30-day annualized volatility (55%). Keep initial position sizes smaller and use wider stop-review levels.
NSE MCP Live & 5-Year Check No API Key
Algorithmic Momentum Prediction & Optimal Entry PriceWAIT FOR PULLBACK (BUY ON DIPS) (Score 85/100)
Trend is strong (+13.9% above 50-DMA), so chasing at Rs 1,024.60 carries pullback risk. Better entry price: wait for a dip into Rs 890.91 – Rs 926.91 (near 20/50-DMA), with review stop at Rs 702.92 and target Rs 1,279.69.
| Optimal Support area | Tranche 1 (50%) | Tranche 2 (50%) | Risk level / Review | Level 1 (Swing) | Level 2 (Breakout) | Risk : Reward |
|---|---|---|---|---|---|---|
| Rs 890.91 – Rs 926.91 Ideal ~Rs 908.91 |
Rs 926.91 | Rs 890.91 | Rs 702.92 ATR 4.2% |
Rs 1,279.69 | Rs 1,526.88 | 1 : 1.8 RSI 68 · Vol 2.13x |
Live Candlestick & TradingView Chart (AARTIPHARM)
MARKET CLOSED - EOD SNAPSHOTKey figures
P/E42.8sector median 42.8
P/B5.28xprice / book value
EPSRs 23.93grew 12.1% a year
Dividend yield-from saved dividend events
Debt to equity0.15xnet debt Rs 240 Cr
Sales growth-4.8%a year over 1 years
Profit growth11.9%a year over 1 years
Operating margin20.8%net margin 11.7%
Company Debt, Borrowings & Cash Flow Health
Total Debt / Loans
Rs 264 Cr
Increased +Rs 50.1 Cr YoY
Cash & Bank Balances
Rs 24.1 Cr
Liquid cash & equivalents
Net Debt (Loans − Cash)
Rs 240 Cr
10.2% of total assets
Debt to Equity & Interest Cover
0.15x D/E
Interest cover: 18.5x EBIT
Operating Cash Flow (OCF)
Rs 216 Cr
OCF/PAT conversion: 100%
Free Cash Flow (FCF)
Rs 60.8 Cr
After Capex of Rs 156 Cr
About AARTI PHARMALABS
Market capNot available
First listed30 Jan 2023BSE not available · NSE 30 Jan 2023
Face valueRs 5
Book valueNot available
ROENot availableReturn on equity
ROCENot availableReturn on capital employed
Profile completeness2 of 8Missing: description, industry, share count, book value, ROE, ROCE
Shareholding
Promoters and group 39.66% -3.20 pp, public 60.34%, as on 30 Sep 2026. Holder names and history
Day range991.45 to 1,031.85Open 1,015.55
52-week high1,047.25
-2.2% from high (17 Nov 2026)
52-week low585.00
+75.1% from low (30 Mar 2026)
Volume5.01 L
0.7x the 20-day average
RSI (14)67
neutral
Volatility (30d)55.2%annualised
Returns
1W+1.4%
1M+23.1%
3M+23.6%
6M+45.6%
1Y+44.7%
YTD+36.2%
3Y a year+36.2%
Against the NIFTY 50
| Period | AARTIPHARM | NIFTY 50 | Difference |
|---|---|---|---|
| 1M | +23.1% | +11.5% | +11.6 pts |
| 3M | +23.6% | +5.3% | +18.3 pts |
| 6M | +45.6% | +7.9% | +37.8 pts |
| 1Y | +44.7% | -2.1% | +46.7 pts |
Risk over the past year
Volatility47%high
Deepest fall-26.3%from a peak
Beta1.17moves more than the index
Best day+20.0%10 Aug 2026
Worst day-7.8%08 Oct 2026
Up days49%of sessions
🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition
Piotroski F-Score: 6 / 9 · Solid Financial Health
3-Step DuPont ROE Identity:
Balanced Profitability & Efficiency
Net Margin: 11.7%
×
Asset Turnover: 0.72x
×
Equity Multiplier: 1.47x
=
ROE 13.1%
✓ Positive Net Profit (PAT > 0)
Rs 216 Cr
✓ Positive Operating Cash Flow (OCF > 0)
Rs 216 Cr
✓ High Cash Conversion (OCF >= 85% of PAT)
100% conversion
⚠ Improving Return on Assets (ROA YoY)
8.4% vs 8.7%
✓ Conservative / Decreasing Debt-to-Equity
0.15x (prev 0.14x)
✓ Healthy Balance Sheet Asset Coverage
3.72x
⚠ Institutional Return on Equity (ROE >= 14%)
13.1%
✓ Stable / Expanding Profit Margin YoY
11.7% vs 9.9%
⚠ Asset Turnover Efficiency (Sales / Assets)
0.72x
Quarterly Results (Last 8 Quarters — QoQ & YoY Acceleration)
| Rs crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales / Revenue | 538 | 564 | 386 | 418 | 432 | 583 | 536 | 610 |
| Sales QoQ % | +17.5% | +4.8% | -31.6% | +8.3% | +3.3% | +35.0% | -8.1% | +13.8% |
| Operating Profit | 129 | 147 | 93.0 | 75.0 | 103 | 113 | 136 | 136 |
| Operating Margin (OPM %) | 24.0% | 26.1% | 24.1% | 17.9% | 23.8% | 19.4% | 25.4% | 22.3% |
| Net Profit (PAT) | 74.0 | 88.0 | 50.0 | 28.0 | 48.0 | 61.0 | 76.0 | 71.0 |
| Profit QoQ % | +34.5% | +18.9% | -43.2% | -44.0% | +71.4% | +27.1% | +24.6% | -6.6% |
| Profit YoY % | +39.6% | +35.4% | -9.1% | -49.1% | -35.1% | -30.7% | +52.0% | +153.6% |
| Net Margin % | 13.8% | 15.6% | 13.0% | 6.7% | 11.1% | 10.5% | 14.2% | 11.6% |
Sales and profit
Sales growth-4.8%a year, 1Y
Profit growth+11.9%a year, 1Y
EPS growth+12.1%a year, 1Y
Avg ROE12.7%2 years
Profit and loss
| Rs crore | FY23 | FY24 |
|---|---|---|
| Sales | 1,945 | 1,853 |
| Sales growth | - | -4.8% |
| Operating profit | 342 | 386 |
| Operating margin | 17.6% | 20.8% |
| Other income | 2.32 | 4.90 |
| Interest | 21.1 | 17.2 |
| Depreciation | 62.5 | 73.2 |
| Profit before tax | 261 | 300 |
| Tax rate | 25.8% | 27.8% |
| Net profit | 193 | 216 |
| Profit growth | - | +11.9% |
| Net margin | 9.9% | 11.7% |
| EPS (Rs) | 21.35 | 23.93 |
Balance sheet
| Rs crore | FY23 | FY24 |
|---|---|---|
| Equity (net worth) | 1,558 | 1,757 |
| Borrowings | 214 | 264 |
| Cash | 25.0 | 24.1 |
| Total assets | 2,231 | 2,582 |
| Debt to equity | 0.14x | 0.15x |
Debt, Loans, Cash Flow & Working Capital
| Rs crore | FY23 | FY24 |
|---|---|---|
| Operating Cash Flow (OCF) | 263 | 216 |
| Capital Expenditure (Capex) | 120 | 156 |
| Free Cash Flow (FCF = OCF - Capex) | 143 | 60.8 |
| OCF / Net Profit Conversion | 1.36x | 1.00x |
| Total Borrowings / Loans | 214 | 264 |
| Cash & Bank Balances | 25.0 | 24.1 |
| Trade Receivables (Cr) | 440 | 519 |
| Receivable Days | 82.57x | 102.32x |
| Inventories (Cr) | 602 | 643 |
| Inventory Days | 112.97x | 126.66x |
Returns on capital
| Rs crore | FY23 | FY24 |
|---|---|---|
| ROE | 12.4% | 13.1% |
| ROCE | 17.2% | 18.0% |
| Interest cover | 13.39x | 18.46x |
Compared with its sector Pharma & Healthcare
| Stock | Price | Day | 1 year | Mkt cap (Cr) | P/E | P/B | ROE | Net margin |
|---|---|---|---|---|---|---|---|---|
| ALIVUSALIVUS LIFE SCIENCES LTD | 1,449.90 | +0.4% | - | 17,769 | 37.7 | 7.6 | 20.2% | 20.6% |
| CAPLIPOINTCAPLIN POINT LAB LTD. | 2,084.60 | -0.0% | - | 15,833 | 34.6 | 6.8 | 19.7% | 27.0% |
| AARTIPHARMAARTI PHARMALABS LIMITED | 1,024.60 | +1.1% | - | 9,285 | 42.8 | 5.3 | 12.3% | 11.7% |
| BLUEJETBLUE JET HEALTHCARE LTD | 516.85 | -0.3% | - | 8,965 | 54.8 | 10.6 | 19.4% | 23.0% |
| AARTIDRUGSAARTI DRUGS LTD. | 498.90 | -1.4% | - | 4,587 | 26.9 | 3.6 | 13.4% | 6.8% |
| DIVISLABDIVI S LABORATORIES LTD | 11,178.00 | +1.2% | - | - | 115.6 | - | 15.3% | 24.3% |
| WOCKPHARMAWOCKHARDT LIMITED | 2,187.00 | +7.9% | - | - | - | - | - | - |
| LAURUSLABSLAURUS LABS LIMITED | 2,306.00 | -0.7% | - | - | - | - | - | - |
| SUNPHARMASUN PHARMACEUTICAL IND L | 1,900.00 | +1.5% | - | - | - | - | - | - |
| MAXHEALTHMAX HEALTHCARE INS LTD | 1,040.65 | +1.7% | - | - | - | - | - | - |
| CIPLACIPLA LTD | 1,418.50 | +0.1% | - | - | 29.5 | - | - | 13.7% |
| APOLLOHOSPAPOLLO HOSPITALS ENTER. L | 8,738.00 | -0.9% | - | - | 64.7 | - | 21.1% | 7.9% |
| Sector median | - | 42.8 | 6.8 | 13.4% |
Today: 15 minute chart and signal
Analysis and next-session reading
Signals
Price is above its 50-day average
20-day average is above the 50-day (short-term uptrend)
Price is above its 200-day average (long-term uptrend)
RSI 67: neutral
Trading within 3% of its 52-week high
When is a good price?
The price is in the upper quarter of its 1-year range and is lower than it was on 0% of days in the past year.
Support (prices below today's)
| 50-day average | 899.91 | -12.2% |
| 20-day low | 782.00 | -23.7% |
| 60-day low | 765.00 | -25.3% |
| 200-day average | 760.39 | -25.8% |
| 52-week low | 585.00 | -42.9% |
Resistance (prices above today's)
| 20-day high | 1,047.25 | +2.2% |
| 60-day high | 1,047.25 | +2.2% |
| 52-week high | 1,047.25 | +2.2% |
Zones buyers often watch
| Lower quarter of the 1-year range | 585.00 to 700.56 | Historically the cheapest part of the past year. |
| Pullback of 10% to 20% from the high | 837.80 to 942.53 | A common area for dips inside an uptrend. |
| Around the 200-day average | 737.58 to 783.20 | Long-term trend line, often watched as support. |
Moving averages and momentum
| Indicator | Value | Reading |
|---|---|---|
| 20-day average | 926.38 | Price is 10.6% above |
| 50-day average | 899.91 | Price is 13.9% above |
| 200-day average | 760.39 | Price is 34.7% above |
| RSI (14) | 67 | Neutral |
| MACD (12, 26, 9) | 36.22 | Above its signal line (momentum rising) |
| Volatility (30d) | 55.2% | High yearly swings |
Support and resistance
R21,056.37
R11,040.48
Pivot1,015.97
S11,000.08
S2975.57
| Date | Open | High | Low | Close | Change | Volume |
|---|---|---|---|---|---|---|
| 2026-11-19 | 1,015.55 | 1,031.85 | 991.45 | 1,024.60 | +1.11% | 501,333 |
| 2026-11-18 | 1,007.00 | 1,028.95 | 992.45 | 1,013.40 | -0.25% | 576,603 |
| 2026-11-17 | 983.00 | 1,047.25 | 980.75 | 1,015.90 | +2.95% | 905,080 |
| 2026-11-16 | 990.00 | 1,023.80 | 979.65 | 986.75 | -1.12% | 846,773 |
| 2026-11-13 | 1,015.00 | 1,019.50 | 989.70 | 997.95 | -1.24% | 615,922 |
| 2026-11-12 | 929.00 | 1,019.00 | 924.80 | 1,010.50 | +9.42% | 1,779,924 |
| 2026-11-11 | 936.00 | 941.85 | 920.05 | 923.50 | +0.23% | 353,214 |
| 2026-11-09 | 924.10 | 960.00 | 915.60 | 921.40 | -0.89% | 503,721 |
| 2026-11-06 | 920.00 | 932.70 | 900.00 | 929.10 | +0.09% | 434,680 |
| 2026-11-05 | 945.00 | 946.50 | 917.55 | 928.30 | +0.19% | 327,862 |
| 2026-11-04 | 927.40 | 934.50 | 912.60 | 926.50 | +0.71% | 352,298 |
| 2026-11-03 | 898.00 | 931.20 | 895.00 | 919.95 | +3.50% | 675,997 |
| 2026-11-02 | 873.20 | 898.55 | 870.05 | 888.80 | +1.84% | 464,241 |
| 2026-10-30 | 938.00 | 938.00 | 865.00 | 872.70 | -5.92% | 643,478 |
| 2026-10-29 | 900.00 | 970.00 | 855.00 | 927.65 | +5.18% | 3,482,346 |
| 2026-10-28 | 892.50 | 898.90 | 869.40 | 881.95 | -0.45% | 466,961 |
| 2026-10-27 | 830.00 | 890.60 | 816.40 | 885.90 | +7.63% | 556,818 |
| 2026-10-26 | 820.00 | 843.00 | 811.00 | 823.10 | +0.27% | 323,611 |
| 2026-10-23 | 832.00 | 832.00 | 782.00 | 820.85 | -0.96% | 702,860 |
| 2026-10-22 | 840.00 | 844.00 | 821.00 | 828.80 | -1.71% | 414,639 |
| 2026-10-21 | 842.00 | 852.10 | 825.70 | 843.25 | +1.31% | 650,314 |
| 2026-10-19 | 879.00 | 879.00 | 830.80 | 832.35 | -4.73% | 451,955 |